MentionFox
Home › Executive changes › Immunocore Holdings plc
Leadership changes · IMCR · SEC Form 8-K, Item 5.02

Leadership changes at Immunocore Holdings plc (2026)

Before you join, sell to or invest in Immunocore Holdings plc

MentionFox check on Immunocore Holdings plc: only 1 source on file so far (checked 14 November 2026). Run a full check before you rely on it. mentionfox.com/c/executive-changes/immunocore-holdings

Check Immunocore Holdings plc before you join, sell or invest Free, no sign-up: every record on file, each linked to its source.

What do you want to do about Immunocore Holdings plc?

Who joined and who left Immunocore Holdings plc (IMCR)? 1 departure reported on 2026-01-30, each cited to the company's own filing.

As of November 14, 2026, Immunocore Holdings plc has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on January 30, 2026, naming 1 departure. The latest filing names David Berman, leaving (Form 8-K, January 30, 2026).

29 companies changed executives this week, 1 had other signals.

Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.

ONITY GROUP INC.announced the departure of its Chief Investment Officer
Adicet Bio, Inc.announced the departure of its Director
MAMMOTH ENERGY SERVICES, INC.announced the departure of its Chief Operating Officer
CERENOME, INC.named a new Director
Cohen & Co Inc.named a new Chief Executive Officer
Check one company free All companies that changed executives this week

ELI LILLY & Co also filed stake reports on 5 other companies ↓

Sell to companies like Immunocore Holdings plc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Opens in a new tab. No signup.

Changes1
Out (departing)1
Latest filing2026-01-30

Immunocore Holdings plc reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-01-30. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Immunocore Holdings plc files it.

Also on the record for Immunocore Holdings plc

DateRecordFigureOur pageSource
November 9, 2026Stake report, Schedule 13G, by Point72 Asset Management, L.P.5.2% of the class5%+ stakesSource
October 7, 2026Stake report, Schedule 13G/A, by FMR LLC3.6% of the class5%+ stakesSource
August 14, 2026Stake report, Schedule 13G/A, by Vestal Point Capital, LP3.5% of the class5%+ stakesSource
August 13, 2026Stake report, Schedule 13G/A, by Wellington Management Group LLP11.6% of the class5%+ stakesSource
August 6, 2026Stake report, Schedule 13G/A, by FMR LLC8.8% of the class5%+ stakesSource
May 15, 2026Stake report, Schedule 13G, by Vestal Point Capital, LP5.5% of the class5%+ stakesSource
May 15, 2026Stake report, Schedule 13G/A, by T. Rowe Price Investment Management, Inc.3.7% of the class5%+ stakesSource
March 6, 2026Stake report, Schedule 13G/A, by T. Rowe Price Investment Management, Inc.6% of the class5%+ stakesSource
February 17, 2026Stake report, Schedule 13G/A, by T. Rowe Price Investment Management, Inc.11.8% of the class5%+ stakesSource
November 14, 2025Stake report, Schedule 13G, by Bellevue Group AG5.6% of the class5%+ stakesSource
October 24, 2025Stake report, Schedule 13G, by TANG CAPITAL MANAGEMENT, LLC5.2% of the class5%+ stakesSource
October 3, 2025Stake report, Schedule 13G/A, by ELI LILLY & Co—5%+ stakesSource

Selling to them or working with them? See who runs Immunocore Holdings plc now and the warning signs.

Free to see. No signup.

Keep reading

More on Immunocore Holdings plc and the records around it.

Immunocore Holdings plc elsewhere on the record

Companies that share a holder

Want the whole picture on Immunocore Holdings plc?

Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC

A Full Report on Immunocore Holdings plc: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Immunocore Holdings plc covers

  1. The Short Answer

  2. Which Company This Is

  3. What They Do, And How The Money Works

  4. Who Runs It, And How To Reach Them

  5. The Money: Funding, Valuation, Runway

  6. Who Pays Them, And Who They Are Up Against

  7. Warning Bells

  8. Sources

    13 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

See a sample report

First screen of a real sample Full Report on EchoStar: the verdict, 17 sections, 63 cited sources, built 2026-10-21A real finished report, first screen. Opens in a new tab.

The newest 12 of 15 records.

Timeline

FiledIn / outPersonRoleEffectiveSource
2026-01-30Out2026-02-278-K, 2026-01-30

Why did they leave? What the filings say

For each named departure below, the sentence from the company's own filing that gives a reason, word for word. Where a filing gives none, it says so here; nothing is inferred.

Selling to Immunocore Holdings plc?

New leaders reset buying decisions — get the Full Report on Immunocore Holdings plc: who runs it, how the money works and what to watch, every claim linked to its source.

Get the Full Report

Watch Immunocore Holdings plc

Hiring for a seat like this?

Find people with the same kind of experience as the senior executive at Immunocore Holdings plc, with the record behind each one.

Find candidates like senior executive at Immunocore Holdings plc

Every change, in the filing's words

Filed 2026-01-30 · 8-K

Departing: David Berman, effective 2026-02-27

On January 27, 2026, David Berman notified Immunocore Holdings plc (the "Company") of his decision to resign as Head of Research & Development of the Company, effective as of February 27, 2026, in order to pursue another opportunity.

Also stated in this filing

  • The Company will not seek a direct replacement for Dr. Berman but will streamline and leverage its existing R&D structure.

Tools for this story

Each opens in a new tab, filled in for Immunocore Holdings plc. With no account yet, you sign up free and land on the result.

Where this comes from

A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.

Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.

Not for employment, credit or tenancy decisions. MentionFox research is for sales, partnership and investor research. Permitted use

Cite this page

Permanent URL: https://mentionfox.com/executive-changes/immunocore-holdings
Last updated 2026-11-14
Primary record: SEC filing 1 · SEC filing 2 · SEC filing 3 · SEC filing 4
Immunocore Holdings plc executive departure 2026. MentionFox, 2026-11-14. https://mentionfox.com/executive-changes/immunocore-holdings